ROCO
4109
Market cap40mUSD
Oct 08, Last price
10.95TWD
1D
-0.45%
1Q
-8.75%
Jan 2017
-52.04%
IPO
-26.66%
Name
Jia Jie Biomedical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jia Jie Biomedical Co., Ltd., headquartered in Kaohsiung, Taiwan, was established in 1995. Formerly known as Murad Chia Jei Biotechnology Co., Ltd. until its rebranding in June 2019, the company primarily specializes in the production and distribution of health foods and wellness products across both Taiwan and Mainland China. The company's core operations encompass the processing, sale, and trade of softshell turtle-derived food items, as well as the manufacturing of dairy products. Its diversified food portfolio also features a range of specialty items such as softshell turtle egg powder capsules, enzyme powders, tortoise jelly, softshell turtle oil, and various other encapsulated nutritional supplements. Beyond its food production, Jia Jie Biomedical engages in comprehensive import/export activities, product distribution, and managing bidding and quotation procedures for its offerings. It also operates as a wholesaler for a broad array of consumer goods, including non-alcoholic beverages, confectioneries, baked goods, dietary supplements, general groceries, everyday household items, and cosmetics. Further expanding its business scope, the company manufactures water purification systems and their associated components, provides brokerage services for life and property insurance, and invests in the research, development, and production of advanced aquatic product technologies and various biological solutions.
Key people
Chung-Chun Wong
Chairman of the Board · since 2024
Wenzhong Wu
Chief Operating Officer · since 2020
General Manager · since 2021
Zhenyi Jiang
Deputy General Manager · since 1995
Qinghong Lin
Deputy General Manager-Finance Division, Corporate Governance Officer · since 2023
Yiqian Zhong
Deputy General Manager · since 2018
Shujuan Cai
Director · since 2018
Chief Executive Officer, Director · since 2024
Junyi Huang
Director · since 2023
Gengxian Wu
Director · since 2018
Jinkun Xie
Director
Director · since 2023
Weiting Xie
Director · since 2018
Bosheng Zhang
Director · since 2023
Independent Director · since 2020
Chia-Liang Kao
Independent Director · since 2023
Hui-Ming Tsai
Independent Director · since 2023
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||